Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Machine Model Exponentially Shortens Expert Review Period for COVID-19 Treatments and Vaccines

By HospiMedica International staff writers
Posted on 07 May 2020
Researchers are using an artificial intelligence (AI) powered tool to speed up the search for COVID-19 treatments and vaccines that makes it possible to prioritize resources for the most promising studies and ignore research that is unlikely to yield benefits.

The algorithm developed by Northwestern University (Evanston, IL, USA) researchers predicts which studies’ results are most likely to be replicable. More...
Replication, which means that the results of the study can be produced a second time with a new test population, is a key signal that study conclusions are valid. With the new AI tool, researchers can bypass the human-scoring method, allowing the research community and policymakers to make faster decisions about how to prioritize time and funding on the studies that are most likely to succeed.

In comparison to the average time of about 314 days required for the human process, the machine model can scale up to review a larger number of papers in minutes. The machine model is as accurate as scientific experts who review and rate submitted research studies based on how likely they are to be replicable. Used on its own, the model has comparable accuracy to the DARPA SCORE method. In fact, the researchers believe that the machine model’s prediction of the likelihood of replicability may actually be more accurate than the traditional human-scoring prediction, as it considers more of the narrative of the study, while expert reviewers tend to focus on the strength of the relational statistics in a paper.

When paired together, the combination of human-machine approach predicts which findings will be replicable with even greater accuracy than either method on its own, the researchers found. Because the algorithm examines the words of thousands of papers, it recognizes word-choice patterns that might be hidden from human consciousness. It has a much bigger schema to draw upon for its predictions, which makes it an extraordinary partner for human reviewers. The researchers’ model can be used immediately to analyze COVID-related research papers and quickly determine which show the most promise.

“In the midst of a public health crisis, it is essential that we focus our efforts on the most promising research. This is important not only to save lives, but also to quickly tamp down the misinformation that results from poorly conducted research,” said Northwestern’s Brian Uzzi, who led the study. “This tool is particularly useful in this crisis situation where we can’t act fast enough. It can give us an accurate estimate of what’s going to work and not work very quickly. We’re behind the ball, and this can help us catch up.”


Related Links:
Northwestern University


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.